Korean J Gastroenterol.  2014 Sep;64(3):127-132. 10.4166/kjg.2014.64.3.127.

Current Issues on Gastroesophageal Reflux Disease

• Kim JH
• Kim BJ
• Kim SW
• Kim SE
• Kim YS
• Sung HY
• Oh TH
• Jeong ID
• Park MI
• The Korean Society of Neurogastroenterology and Motility GERD and Esophageal Function Research Committee

• KMID: 2160653
• DOI: http://doi.org/10.4166/kjg.2014.64.3.127

Abstract

Gastroesophageal reflux disease (GERD) is one of the most common problems in gastrointestinal disorders. With the increase in our understanding on the pathophysiology of GERD along with the development of proton pump inhibitors, the diagnostic and therapeutic approaches to GERD have changed dramatically over the past decade. However, GERD still poses a problem to many clinicians since the spectrum of the disease has evolved to encompass more challenging presentations such as refractory GERD and extraesophageal manifestations. This has led to significant confusion regarding the optimal approach to these patients. This article aims to discuss current issues on GERD.

Keyword

Gastroesophageal reflux; Pathophysiology; Diagnosis; Therapeutics

MeSH Terms

Alginates/therapeutic use
Endoscopy, Gastrointestinal
Esophageal pH Monitoring
GABA-B Receptor Agonists/therapeutic use
Gastroesophageal Reflux/*diagnosis/drug therapy/pathology
Humans
Metoclopramide/therapeutic use
Proton Pump Inhibitors/therapeutic use
Alginates
GABA-B Receptor Agonists
Metoclopramide
Proton Pump Inhibitors

Reference

References

1. Beaumont H, Bennink RJ, de Jong J, Boeckxstaens GE. The position of the acid pocket as a major risk factor for acidic reflux in healthy subjects and patients with GORD. Gut. 2010; 59:441–451.

2. Fletcher J, Wirz A, Young J, Vallance R, McColl KE. Unbuffered highly acidic gastric juice exists at the gastroesophageal junction after a meal. Gastroenterology. 2001; 121:775–783.

3. Boeckxstaens GE, Rohof WO. Pathophysiology of gastroesophageal reflux disease. Gastroenterol Clin North Am. 2014; 43:15–25.

4. Sifrim D, Castell D, Dent J, Kahrilas PJ. Gastro-oesophageal reflux monitoring: review and consensus report on detection and definitions of acid, nonacid, and gas reflux. Gut. 2004; 53:1024–1031.

5. Jung HK, Hong SJ, Jo YJ, et al. Korean Society of Neurogastroenterology and Motility. Updated guidelines 2012 for gastroesophageal reflux disease. Korean J Gastroenterol. 2012; 60:195–218.

6. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013; 108:308–328.

7. Hirano I, Richter JE. Practice Parameters Committee of the American College of Gastroenterology. ACG practice guidelines: esophageal reflux testing. Am J Gastroenterol. 2007; 102:668–685.

8. Cool M, Poelmans J, Feenstra L, Tack J. Characteristics and clinical relevance of proximal esophageal pH monitoring. Am J Gastroenterol. 2004; 99:2317–2323.

9. Gyawali CP. High resolution manometry: the Ray Clouse legacy. Neurogastroenterol Motil. 2012; 24(Suppl 1):2–4.

10. Mello M, Gyawali CP. Esophageal manometry in gastroesophageal reflux disease. Gastroenterol Clin North Am. 2014; 43:69–87.

11. Frankhuisen R, Van Herwaarden MA, Scheffer RCh, Hebbard GS, Gooszen HG, Samsom M. Increased intragastric pressure gra-dients are involved in the occurrence of acid reflux in gastroesophageal reflux disease. Scand J Gastroenterol. 2009; 44:545–550.

12. Khajanchee YS, Cassera MA, Swanström LL, Dunst CM. Diagnosis of Type-I hiatal hernia: a comparison of high-reso-lution manometry and endoscopy. Dis Esophagus. 2013; 26:1–6.

13. Chan WW, Haroian LR, Gyawali CP. Value of preoperative esophageal function studies before laparoscopic antireflux surgery. Surg Endosc. 2011; 25:2943–2949.

14. Jobe BA, Richter JE, Hoppo T, et al. Preoperative diagnostic work-up before antireflux surgery: an evidence and experience-based consensus of the Esophageal Diagnostic Advisory Panel. J Am Coll Surg. 2013; 217:586–597.

15. Ghosh SK, Pandolfino JE, Kwiatek MA, Kahrilas PJ. Oesophageal peristaltic transition zone defects: real but few and far between. Neurogastroenterol Motil. 2008; 20:1283–1290.

16. Kumar N, Porter RF, Chanin JM, Gyawali CP. Analysis of inter-segmental trough and proximal latency of smooth muscle con-traction using high-resolution esophageal manometry. J Clin Gastroenterol. 2012; 46:375–381.

17. Armstrong D, Marshall JK, Chiba N, et al. Canadian Association of Gastroenterology GERD Consensus Group. Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults: update 2004. Can J Gastroenterol. 2005; 19:15–35.

18. Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology. 2008; 135:1383–1391.e5.

19. Fock KM, Talley NJ, Fass R, et al. Asia-Pacific consensus on the management of gastroesophageal reflux disease: update. J Gastroenterol Hepatol. 2008; 23:8–22.

20. Shaheen NJ, Weinberg DS, Denberg TD, Chou R, Qaseem A, Shekelle P. Clinical Guidelines Committee of the American College of Physicians. Upper endoscopy for gastroesophageal reflux disease: best practice advice from the clinical guidelines committee of the American College of Physicians. Ann Intern Med. 2012; 157:808–816.

21. Sharma P, Shaheen NJ, Perez MC, et al. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation– results from two randomized controlled studies. Aliment Pharmacol Ther. 2009; 29:731–741.

22. Fass R, Murthy U, Hayden CW, et al. Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy-a prospective, randomized, multi-centre study. Aliment Pharmacol Ther. 2000; 14:1595–1603.

23. Zerbib F, Roman S, Ropert A, et al. Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy. Am J Gastroenterol. 2006; 101:1956–1963.

24. Zhang Q, Lehmann A, Rigda R, Dent J, Holloway RH. Control of transient lower oesophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in patients with gastro-oesophageal reflux disease. Gut. 2002; 50:19–24.

25. Rohof WO, Lei A, Hirsch DP, et al. The effects of a novel metabotropic glutamate receptor 5 antagonist (AZD2066) on transient lower oesophageal sphincter relaxations and reflux episodes in healthy volunteers. Aliment Pharmacol Ther. 2012; 35:1231–1242.

26. Hershcovici T, Fass R. Gastro-oesophageal reflux disease: be-yond proton pump inhibitor therapy. Drugs. 2011; 71:2381–2389.

27. Vela MF, Craft BM, Sharma N, Freeman J, Hazen-Martin D. Refractory heartburn: comparison of intercellular space diame-ter in documented GERD vs. functional heartburn. Am J Gastroenterol. 2011; 106:844–850.

28. Yoshida N, Kamada K, Tomatsuri N, et al. Management of recurrence of symptoms of gastroesophageal reflux disease: syn-ergistic effect of rebamipide with 15 mg lansoprazole. Dig Dis Sci. 2010; 55:3393–3398.

29. Adachi K, Furuta K, Miwa H, et al. A study on the efficacy of rebamipide for patients with proton pump inhibitor-refractory nonerosive reflux disease. Dig Dis Sci. 2012; 57:1609–1617.

30. Viazis N, Keyoglou A, Kanellopoulos AK, et al. Selective serotonin reuptake inhibitors for the treatment of hypersensitive esophagus: a randomized, double-blind, placebo-controlled study. Am J Gastroenterol. 2012; 107:1662–1667.

31. Dickman R, Schiff E, Holland A, et al. Clinical trial: acupuncture vs. doubling the proton pump inhibitor dose in refractory heartburn. Aliment Pharmacol Ther. 2007; 26:1333–1344.

32. Jones H, Cooper P, Miller V, Brooks N, Whorwell PJ. Treatment of non-cardiac chest pain: a controlled trial of hypnotherapy. Gut. 2006; 55:1403–1408.

33. Rohof WO, Bennink RJ, de Ruigh AA, Hirsch DP, Zwinderman AH, Boeckxstaens GE. Effect of azithromycin on acid reflux, hiatus hernia and proximal acid pocket in the postprandial period. Gut. 2012; 61:1670–1677.

34. Rohof WO, Bennink RJ, Smout AJ, Thomas E, Boeckxstaens GE. An alginate-antacid formulation localizes to the acid pocket to re-duce acid reflux in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2013; 11:1585–1591.

35. Kim D, Velanovich V. Surgical treatment of GERD: where have we been and where are we going? Gastroenterol Clin North Am. 2014; 43:135–145.

36. Rodríguez L, Rodriguez P, Gómez B, et al. Long-term results of elec-trical stimulation of the lower esophageal sphincter for the treatment of gastroesophageal reflux disease. Endoscopy. 2013; 45:595–604.